Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials

BACKGROUND: Immuno-oncology (IO) agents have demonstrated efficacy across many tumor types and have led to change in standard of care. In breast cancer, atezolizumab and pembrolizumab were recently FDA-approved in combination with chemotherapy specifically for patients with PD-L1-positive metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Schreiber, Anna R., Kagihara, Jodi A., Weiss, Jennifer A., Nicklawsky, Andrew, Gao, Dexiang, Borges, Virginia F., Kabos, Peter, Diamond, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010246/
https://www.ncbi.nlm.nih.gov/pubmed/33816286
http://dx.doi.org/10.3389/fonc.2021.640690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010246/
https://www.ncbi.nlm.nih.gov/pubmed/33816286
http://dx.doi.org/10.3389/fonc.2021.640690

Ejemplares similares